research 050 Evaluation of 3 month data for the use of erenumab for chronic migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.
Search
forResearch
3 / 1000+ resultsresearch Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Pharmaceutical and non-pharmaceutical treatments for migraine: a systematic review of efficacy and safety
Both new medications and non-drug treatments can effectively manage migraines with fewer side effects.
Learn
— no results
Community Join
— no results
Experts
— no results
Clinics
— no results